Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl]) for ...

Please provide your email address to receive an email when new articles are posted on . Onapgo is the first subcutaneous apomorphine infusion device approved to treat motor fluctuations in Parkinson’s ...

Some eight months into the launch of Onapgo, the Parkinson’s disease infusion pump Supernus Pharmaceuticals spent years fighting to get across the FDA finish line, the drugmaker is discovering that ...

ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...

(RTTNews) - Supernus Pharmaceuticals, Inc. (SUPN), a biopharmaceutical company, announced on Tuesday the FDA approval of ONAPGO or apomorphine hydrochloride for the treatment of motor fluctuations in ...

The US Food and Drug Administration (FDA) has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection to treat motor fluctuations in adults with advanced Parkinson’s disease ...

Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. On its fourth attempt to pass muster with the FDA, the company’s SPN-830, now branded as ...

For full year 2026, Dec projected "total revenues to range from $840 million to $870 million, comprised of net product sales, ZURZUVAE collaboration revenues and royalty and licensing revenues." ...

Dec announced updated full-year 2025 guidance, expecting "total revenue to range from $685 million to $705 million, up from the previous range of $670 million to $700 million, comprised of net product ...

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) gained in the premarket on Thursday after Piper Sandler upgraded the neurology-focused drug developer to Overweight from Neutral, citing a promising ...